<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335869">
  <stage>Registered</stage>
  <submitdate>20/08/2010</submitdate>
  <approvaldate>24/08/2010</approvaldate>
  <actrnumber>ACTRN12610000701022</actrnumber>
  <trial_identification>
    <studytitle>Study to Determine the Accuracy of Prothrombin Time of Warfarinised blood.</studytitle>
    <scientifictitle>In patients taking warfarin, how do the Prothrombin(PT)/International Normalised Ratio (INR) results from Universal Biosensors, CoaguChek point-of-care INR devices correlate to a standard laboratory laboratory method.</scientifictitle>
    <utrn>N/A</utrn>
    <trialacronym>N/A</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>A prothrombin time test (PT) used to monitor patients taking the anticoagulant warfarin</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The aim of this study is to measure prothrombin time (PT) expressed in International Normalised Ratio (INR) units in persons receiving warfarin treatment on an experimental device, commercially available point of care device and a standard laboratory method.
This will involve taking a venous sample from both persons receiving warfarin treatment (experimental group) and persons not receiving warfarin treatment (control group). All persons are currently undergoing testing at a clinic. Samples collected are tested by laboratory staff on the experimental point of care device, commercially available device and standard laboratory reference instrument. 
It is expected that the persons participation does not exceed the time it takes to complete informed consent form and have a venous sample collected.</interventions>
    <comparator>No treatments are administered as part of this study. Control group are subjects not receiving warfarin treatment.</comparator>
    <control>Active</control>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>International Normalised Ratio(INR) values from the Universal Biosensors device will correlate with results obtained from the Roche CoaguChek and the laboratory reference method.</outcome>
      <timepoint>Results will be displayed immediately</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>International Normalised Ratio(INR) values from the Universal Biosensors device will correlate with results obtained from the Roche CoaguChek and the laboratory reference method over the extended range of haematocrits.</outcome>
      <timepoint>Results will be displayed immediately.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients currently receiving warfarin treatment
Patients not receiving warfarin treatment</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>None</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>4/04/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Universal Biosensors Pty Ltd</primarysponsorname>
    <primarysponsoraddress>1 Corporate Ave.
Rowville, VIC</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Universal Biosensors Pty Ltd</fundingname>
      <fundingaddress>1 Corporate Ave.
Rowville, VIC</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will involve taking a venous sample from both persons receiving warfarin treatment (experimental group) and persons not receiving warfarin treatment (control group). All persons are currently undergoing testing at a clinic. Samples collected are tested by laboratory staff on the experimental point of care device, commercially available device and standard laboratory reference instrument. 
The aim of this study is to measure prothrombin time (PT) expressed in International Normalised Ratio (INR) units in persons receiving warfarin treatment on an experimental device, commercially available point of care device and a standard laboratory method.
It is expected that International Normalised Ratio(INR) values from the Universal Biosensors device will correlate with results obtained from the Roche CoaguChek and the laboratory reference method.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital Ethics Committee</ethicname>
      <ethicaddress>55 Commercial Road
Melbourne 3004</ethicaddress>
      <ethicapprovaldate>13/01/2011</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>23/08/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Newman</name>
      <address>1 Corporate Ave.
Rowville VIC, 3178</address>
      <phone>+ 61 3 9213 9003</phone>
      <fax>+ 61 3 9213 9099</fax>
      <email>pnewman@universalbiosensors.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kristyn Forsayeth</name>
      <address>1 Corporate Ave.
Rowville VIC, 3178</address>
      <phone>+61 3 9213 9000</phone>
      <fax>+61 3 9213 9099</fax>
      <email>kforsayeth@universalbiosensors.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kristyn Forsayeth</name>
      <address>1 Corporate Ave.
Rowville VIC, 3178</address>
      <phone>+ 61 3 9213 9000</phone>
      <fax>+ 61 3 9213 9099</fax>
      <email>kforsayeth@universalbiosenors.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>